Publicaciones en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (16)

2024

  1. ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression

    International Journal of Molecular Sciences, Vol. 25, Núm. 6

2023

  1. Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications

    Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257

2022

  1. ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology

    Cancers, Vol. 14, Núm. 14

2021

  1. Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer

    npj Precision Oncology, Vol. 5, Núm. 1

2019

  1. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1

  2. MEK5 promotes lung adenocarcinoma

    The European respiratory journal

2017

  1. ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA

    Oncogene, Vol. 36, Núm. 12, pp. 1733-1744

2014

  1. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

    Oncogene, Vol. 33, Núm. 2, pp. 148-156

2013

  1. Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue

    Stem Cells, Vol. 31, Núm. 6, pp. 1075-1085

2009

  1. ERK2, but not ERK1, mediates acquired and "De novo" resistance to imatinib mesylate: Implication for CML therapy

    PLoS ONE, Vol. 4, Núm. 7

2008

  1. Neuregulins and cancer

    Clinical Cancer Research, Vol. 14, Núm. 11, pp. 3237-3241

2007

  1. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer

    Journal of Clinical Oncology, Vol. 25, Núm. 19, pp. 2656-2663

  2. The extracellular linker of pro-neuregulin-α2c is required for efficient sorting and juxtacrine function

    Molecular Biology of the Cell, Vol. 18, Núm. 2, pp. 380-393

2005

  1. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin

    Cancer Research, Vol. 65, Núm. 15, pp. 6801-6810

  2. Bortezomib is an efficient agent in plasma cell leukemias

    International Journal of Cancer, Vol. 114, Núm. 4, pp. 665-667

  3. Multifunctional role of Erk5 in multiple myeloma

    Blood, Vol. 105, Núm. 11, pp. 4492-4499